<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404404</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000515534</org_study_id>
    <secondary_id>PREMIERE-AVF3678s</secondary_id>
    <secondary_id>PREMIERE-20061500</secondary_id>
    <secondary_id>GENENTECH-PREMIERE-AVF3678s</secondary_id>
    <secondary_id>ABRAXIS-PREMIERE-AVF3678s</secondary_id>
    <nct_id>NCT00404404</nct_id>
  </id_info>
  <brief_title>ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With Bevacizumab in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Premiere Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some&#xD;
      find tumor cells and kill them or carry tumor-killing substances to them. Others interfere&#xD;
      with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of&#xD;
      tumor cells by blocking blood flow to the tumor. Giving ABI-007 together with bevacizumab may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II is studying how well giving ABI-007 together with bevacizumab works in&#xD;
      treating women with recurrent or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the activity of paclitaxel albumin-stabilized nanoparticle formulation&#xD;
           (ABI-007; Abraxane^®) and bevacizumab, in terms of progression-free survival and&#xD;
           response rate, in women with recurrent or metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the feasibility of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
      Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007; Abraxane^®)&#xD;
      IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and&#xD;
      15. Treatment repeats every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival as measured by RECIST criteria at 1 and 2 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate measured every 3 courses during treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer&#xD;
&#xD;
          -  Recurrent or metastatic disease OR locally recurrent disease not amenable to resection&#xD;
             with curative intent&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  No CNS metastases by CT scan or MRI&#xD;
&#xD;
          -  No HER2-neu-positive tumors&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST ≤ 2 times upper limit of normal (ULN) (5 times ULN if there is known liver&#xD;
             involvement)&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; 1.0 OR proteinuria &lt; 2+ by urine dipstick OR ≤ 1 g&#xD;
             protein on 24-hour urine collection&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancies within the past 5 years except carcinoma in situ of the cervix,&#xD;
             melanoma in situ, or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No inadequately controlled hypertension, defined as systolic blood pressure (BP) &gt; 150&#xD;
             mm Hg and/or diastolic BP &gt; 100 mm Hg on antihypertensive medications&#xD;
&#xD;
          -  No prior hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction or unstable angina within the past 6 months&#xD;
&#xD;
          -  No stroke or transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  No significant vascular disease (e.g., aortic aneurysm or aortic dissection)&#xD;
&#xD;
          -  No symptomatic peripheral vascular disease&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No serious, nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior paclitaxel albumin-stabilized nanoparticle formulation (ABI-007; Abraxane^®)&#xD;
             or bevacizumab&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Prior hormonal therapy for metastatic disease allowed&#xD;
&#xD;
          -  At least 4 weeks since any prior therapy for cancer&#xD;
&#xD;
               -  More than 12 months since prior adjuvant chemotherapy, including use of a taxane&#xD;
&#xD;
          -  More than 28 days since prior major surgery or open biopsy&#xD;
&#xD;
          -  More than 7 days since prior core biopsy or minor surgery (excluding placement of a&#xD;
             vascular access device)&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
          -  No other concurrent therapy for breast cancer&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed if there is bone involvement&#xD;
&#xD;
          -  No concurrent prophylactic granulocyte colony-stimulating factors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linnea Chap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premiere Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

